Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push
CompanyDeals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

CompanyDrug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

CompanyDeals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic
CompanyDrug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates
Company

Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates

CompanyDrug

Biokin Pharma’s BL‑ARC002 Wins NMPA Approval – First‑in‑Class Antibody‑Radionuclide Conjugate Enters Solid Tumor Trials

CompanyDrug

Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs – HS‑20152 and HS‑10587 Enter Clinical Trials in Rare Disease and Oncology

CompanyDeals

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China
CompanyDrug

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

CompanyDrug

GSK Wins FDA Approval for Lynavoy – First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close

Eli Lilly Submits Obesity Policy Recommendations at China Development Forum – Advocates for Weight Management in 15th Five‑Year Plan
Company

Eli Lilly Submits Obesity Policy Recommendations at China Development Forum – Advocates for Weight Management in 15th Five‑Year Plan

Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment – 500‑Subject Reflux Esophagitis Trial Advances Novel PPI
CompanyDrug

Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment – 500‑Subject Reflux Esophagitis Trial Advances Novel PPI